ArticleAnnals of surgical oncology2026
Is Total Neoadjuvant Therapy the Solution to the Lateral Pelvic Lymph Nodes in Rectal Cancer? Retrospective Analysis From a High-Volume Tertiary Care Center.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSelective lateral pelvic lymph node dissection (LPLND) after chemoradiotherapy for persistent nodes is a standard approach for rectal cancer patients with persistently enlarged lateral pelvic nodes (LPLN). The widely adopted Ogura criteria for LPLND selection were based on long-course chemoradiotherapy (LCRT) outcomes. With the rapid adoption of total neoadjuvant therapy (TNT), the relevance of these criteria in the TNT setting remains uncertain. This study aimed to evaluate the role of TNT in managing LPLNs and to identify risk factors for pathologically positive LPLNs (pLPLNs).
methodsThis study retrospectively analyzed patients with locally advanced rectal cancer who underwent LPLND between January 2014 and July 2024. Patients with LPLNs larger than 7 mm at presentation and persistent nodes larger than 4 mm after neoadjuvant therapy underwent LPLND. Risk factors for pLPLN were assesed using multivariable analysis. Local recurrence-free survival (LRFS), disease-free survival (DFS), and overall survival (OS) were estimated using the Kaplan-Meier method.
resultsAmong 228 patients who underwent LPLND, 57 (25 %) had pLPLNs. The internal iliac region was the most common site (47 %). Total neoadjuvant therapy was administered to 118 patients (52 %), with 30 (25.4 %) showing pLPLN after TNT. The significant predictors of pLPLN were cT4b stage (odds ratio [OR], 2.60; 95 % confidence interval [CI], 1.31-5.33; p = 0.007) and multiple enlarged LPLN stations (OR, 3.82; 95 % CI, 1.36-10.98; p = 0.011). Total neoadjuvant therapy was not significantly associated with pLPLN (OR, 2.98; 95 % CI, 0.40-21.88; p = 0.284). The 3-year LRFS was similar between the TNT (90 %) and LCRT (85 %) groups (hazard ratio [HR], 1.31; 95 % CI, 0.56-3.08; p = 0.527).
conclusionThe LCRT- and TNT-treated patients had similar rates of positive lateral nodes. Therefore, the selection criteria for choosing patients for LPLND does not need to change based on the neoadjvuant approach used.
Indexed as
Identifiers
42020914What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.